Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I‐Preserve study

In patients with heart failure (HF) and reduced ejection fraction, decreases or increases in NT‐proBNP levels are associated with better and worse outcomes, respectively. The association in HF and preserved ejection fraction (HF‐PEF) is unknown. We examined the association between change in level of NT‐proBNP and prognosis in patients with HF‐PEF.

[1]  C. O'connor,et al.  Lessons from the TOPCAT trial. , 2014, The New England journal of medicine.

[2]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[3]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[4]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[5]  James D. Thomas,et al.  Impact of Progression of Diastolic Dysfunction on Mortality in Patients With Normal Ejection Fraction , 2012, Circulation.

[6]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[7]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[9]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) , 2011, Circulation. Heart failure.

[10]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective , 2011 .

[11]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[12]  J. Cleland,et al.  The prognostic value of repeated measurement of N‐terminal pro‐B‐type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction , 2009, European journal of heart failure.

[13]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[14]  Karen A. Hartman,et al.  Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. , 2009, Clinical chemistry.

[15]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[16]  C. D. De Pasquale,et al.  Diagnostic and prognostic significance of plasma N-terminal-pro-brain natriuretic peptide in decompensated heart failure with preserved ejection fraction. , 2008, Heart, lung & circulation.

[17]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[18]  A. Lavoinne,et al.  Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system , 2008, Annals of clinical biochemistry.

[19]  P. Grayburn,et al.  Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). , 2007, Journal of cardiac failure.

[20]  Karen A. Hartman,et al.  Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time , 2007, Circulation.

[21]  T. McDonagh,et al.  A change in N‐terminal pro‐brain natriuretic peptide is predictive of outcome in patients with advanced heart failure , 2007, European journal of heart failure.

[22]  A. Rigby,et al.  The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. , 2006, European heart journal.

[23]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[24]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[25]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[26]  S. Yusuf,et al.  Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. , 2005, The American journal of cardiology.

[27]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[28]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[29]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[30]  S. Yusuf,et al.  Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? , 2002, American heart journal.